logo BDSP

Base documentaire


  1. Resource implications of palliative chemotherapy for ovarian cancer.

    Article - En anglais

    Purpose 

    To describe the costs and outcomes of palliative chemotherapy in women with recurrent and refractory ovarian cancer from the perspective of a health care provider.

    Patients and Methods 

    A retrospective study of 40 consecutive women who started second-or third-line chemotherapy for recurrent or refractory ovarian cancer between 1989 and 1992.

    Resource utilization from the commencement of second-or third-line chemotherapy until death or last follow-up evaluation was determined from a detailed chart review.

    All elements of care were recorded, including inpatient admissions, outpatient visits, chemotherapy drugs, nonchemotherapy drugs, radiation therapy, surgical procedures, investigations, and home care.

    Costs calculated using the hotel-approximation method are expressed in 1994 Canadian dollars.

    Actuarial estimates of cost and survival were used to account for censored observations.

    Results 

    After a minimum follow-up period of 24 months, 36 of 40 women had died.

    The median survival duration of the group was 1.1 years from study entry and 1.7 years from first relapse.

    The women received a median of two regimens of chemotherapy (range, one to four) from study entry.

    They spent a median of 33 days as hospital inpatients (mean, 46 ; range, 0 to 185) ; 58% of these inpatient days were for symptomatic management and 32% were for chemotherapy.

    The mean cost per patient was $53,000 (median, $36,600 ; range, $4,800 to $162,900). (...)

    Mots-clés Pascal : Carcinome, Ovaire, Chimiothérapie, Traitement palliatif, Hospitalisation, Analyse coût, Economie santé, Canada, Amérique du Nord, Amérique, Homme, Femelle, Stade avancé, Récidive, Anticancéreux, Tumeur maligne, Appareil génital femelle pathologie, Ovaire pathologie

    Mots-clés Pascal anglais : Carcinoma, Ovary, Chemotherapy, Palliative treatment, Hospitalization, Cost analysis, Health economy, Canada, North America, America, Human, Female, Advanced stage, Relapse, Antineoplastic agent, Malignant tumor, Female genital diseases, Ovarian diseases

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0207694

    Code Inist : 002B02R02. Création : 21/05/1997.